References
- BEATSON GT: On the treatment of inoperable cases ofcarcinoma of the mamma: Suggestions for a new method of treatment, with illustrative cases. Lancet (1986) 11:104–107.
- ELLIS P, CUNNINGHAM D: Management of carcinomasof the upper gastrointestinal tract. Br. Med. J (1994) 308:834–838.
- GALLOWAY DJ, COHEN AM, SHARK B, FRIEDMAN MA:Adjuvant multimodality treatment of rectal cancer. Br, J. Cancer (1989) 76:440–447.
- REHFELD JF: Gastrin and colorectal cancer: A never-ending dispute? Gastroenterology (1995) 108:1307–1310.
- PENMAN ID, EL-OMAR E, ARDILL JES, MCGREGOR JR,GALLOWAY DJ, O'DWYER JP, MCCOLL KEL: Plasma gas-trin concentrations are normal in patients with colo-rectal neoplasia and unaltered following tumor resection. Gastroenterology (1994) 106:1263–1270.
- WATSON SA, STELLE RJC: Gastrin Receptors in Gastrointes-tinal Tumours. RG Landes Company, Austin (1993).
- JESSOP NW, HAY RJ: Characterisation of two rat pancre-atic exocrine cell lines derived from transplantable tumours. In Vitro (1980) 16:212.
- WATSON SA, DURRANT LG, MORRIS DL: Inhibition effectof gastrin receptor antagonist L-365,260 on gastrointes-tinal tumour cells. Cancer (1991) 68:1255–1260.
- BLACKMORE M, HIRST BH: Autocrine stimulation ofgrowth of AR4-2J rat pancreatic tumour cells by gastrin. Br. J. Cancer (1992) 66:32–38.
- WINSETT OE, TOWNSEND CM, GLASS EJ, THOMPSON CJ: Gastrin stimulates growth of colon cancer. Stn. (1986) 99:302–307.
- MCGREGOR DB, JONES RD, KARLIN DA, ROMSDAHL MM: Trophic effects of gastrin on colorectal neoplasms in the rat. Ann. Stag. (1982) 495:219–223.
- KARLIN DA, MCBATH M, JONES RD, ELWYN EK, ROMSDAHL MM: Hypergastrinaemia and colorectal car-cinogenesis in the rat. Cancer Lett. (1985) 29:73–78.
- OSCARSON JAE, VEEN HF, ROSS JS, MALT RA: Dimeiltyl-hydrazine-induced colonic neoplasia: dissociation from endogenous gastrin levels. Stag. (1982) 92:525–530.
- GRAFFNER H, SINGH G, CHAUDRY I, MILSOM JW: Ome-prazole-induced hypergastrinaemia does not influence growth of colon carcinoma. Dig. Dis. Sci. (1992) 37:485–489.
- PINSON DM, HAVU N, SZTERN MI, MATISSON H, LOONEY GA, KIMLER BF: Drug-induced hypergastrinaemia - Ab-sence of trophic effects on colonic-carcinoma in rats. Gastroenterology (1995) 108:1068–1074.
- PENMAN ID, ELOMAR E, MCGREGOR JR, HILLAN O'DWYER PJ, MCCOLL KEL: Omeprazole inhibits colo-rectal carcinogenesis induced by azoxymethane in rats. Gut (1993) 34:1559–1565.
- OCHIAI A, YASUI W, TAHARA E: Growth-promoting effect of gastrin on human gastric carcinoma cell line, TMK-1. Jpn. J. Cancer Res. (GANN) (1985) 76:1064–1071.
- WATSON SA, DURRANT LG, MORRIS DL: Growth-enhanc-ing effects on human gastric and colonic tumour cells. Br. J. Cancer (1989) 59:554–558.
- KUSYK CF, MCNEIL NO, JOHNSON LR: Stimulation of growth of a colon cancer cell line by gastrin. Am. J. Physiol. (1986) 251:G597–G601.
- One of the first studies reporting the mitogenic effects of gastrin on human colon cancer.
- IMDAHL A, EGGSTEIN ST, CRONE C, FAN'FHMANN EH: Growth of colorectal carcinoma cells: regulation in vitro by gastrin, pentagastrin and the gastrin-receptor antagonist, proghmaide. J. Cancer Res. Clin. Oncol. (1989) 115:388–392.
- SMITH JP, FANTASKEY AP, LIU GZ, ZAGON IS: Identifica-tion of gastrin as a growth peptide in human pancreatic cancer. Am. J. Physiol. Reg. Integrative Comp. Physiol. (1995) 37:135–141.
- MOYER MP, ARMSTRONG A, BRADLEY-AUST J, LEVINE BA, SIRINEK KR: Effects of gastrin, glutamine and somato-statin on the in vitro growth of normal and malignant human gastric mucosal cells. Arch. Surg. (1986) 121:285–288.
- Demonstration of a differential effect of gastrin on human gastric cancer cells.
- SIRINEK KR, LEVINE BA, MOYER MP: Pentagastrin stimu-lation in vitro growth of normal and malignant human colon epithelial cells. Am. J. Surg. (1985) 149:35–39
- WATSON SA, DURRANT LG, CROSBIE JD, MORRIS DL: The in vitro growth response of primary human colorectaland gastric cancer cells to gastrin. Int. J. Cancer (1989) 43:692–696.
- Demonstration of a differential gastrin effect on human colorectal cancer cells freshly derived from surgical specimens.
- SUMIYOSHI H, YASUI W, OCHIAI A, TAHARA E: Effects of gastrin on tumour growth and cyclic nucleotide metaholism in xenotransplantable human gastric and colo-nic carcinomas in nude mice. Cancer Res. (1984) 44:4276–4280.
- HOOSEIN NM, KIENER PA, CURRY RC: Anti-proliferative effects of gastrin receptor antagonists and antibodiesto gastrin on human colon carcinoma cell lines. Cancer Res. (1988) 48:7179–7183.
- First identification of a potential autocrine role for gastrin.
- HOOSEIN NM, K1ENER PA, CURRY RC, BRATTAIN MG: Evidence for autocrine growth stimulation of cultured colon tumour cells by a gastrinicholecystokinin-like peptide. Exp. Cell Res. (1990) 186:15–21.
- WATSON SA, DURRANT LG, WENCYK PM, WATSON AL,MORRIS DL: Intracelini2r gastrin Inhuman gastrointes-tinal tumour cells. JNCI (1991) 83:866–872.
- FINLEY GG, KOSKI RA, MELHEM MF, PIPAS MJ, MEISLER Al: Expression of the gastrin gene in the normal human colon and cokorectaladenocarcinoma. CancerRes. (1993) 53:2919–2926.
- Demonstration of widespread occurrence of tumour-associated gas- trin.
- -BALDWIN GS, ZHANG Q-Z: Measurement of gastrin and transforming growth factor a messenger RNA levels in colonic carcinoma cell lines by quantitative polynterase chain reaction. Cancer Res. (1992) 52:2261–2267.
- MONGES G, BIAGINI P, CANTALOUBE JF, CHICHEPOR-TICHE C, FRANCES V, BRANDINI D, PARC P, SEITZ JF, GIOVANNINI M, SAUVAN R, HASSOUN J: Detection of gastrin messenger-RNA in fresh human colonic carci-nomas by reverse transcription-polymerase chain re-action. J. Mol. Endocrinol. (1993) 11:223–229.
- VAN-SOLINGE WW, REHFELD JF: Co-transcription of the gastrin and cholecystokinin genes with selective trans-lation of gastrin mRNA in a human gastric carcinoma cell line. FESS Lett. (1992) 309:47–50.
- SMITH JP, WU Y, MCLAUGHLIN PJ, ZAGON IS: Gastrin stimulates growth of human pancreatic cancer by an autocrine mechanism. EASES J (1995) 9:702.
- KOCHMAN ML, DELVALLE J, DICKINSON CJ, BOLAND CR: Post-translational processing of gastrin in neoplastic human colonic tissues. Biochem. Biophys. Res. Comm. (1992) 189:1165–1169.
- First identification of precursor gastrin accumulation in colonic tumour cells.
- NEMETH J, TAYLOR B, PAUWELS S, VARRO A, DOCICRAY GJ: Identification of progastrin derived peptides in colorectal carcinoma extracts. Gut (1993) 34:90–95.
- VAN-SOLINGE WW, NIELSEN FC, FRIIS-HANSEN L, FALK-MER UG, REHFELD JF: Expression but incomplete matu-ration of progastrin in colorectal carcinomas. Gastroenterology (1993) 104:1099–1107.
- VARRO A, VORONINA S, DOCKRAY GJ: Pathways of processing of the gastrin precursor in rat antral mu-cosa. J. Clin. Invest. (1995) 95:1642–1649.
- Discussion of glycine-extended G17 as a biosynthetic end-product.
- RAISE M, MURAOKA A, TAKEDA H, YAMADA T: Glycine-extended gastrin processing intermediates induce le-ATPase alpha-subunit gene expression. Gastroent-erology (1994) 106:A818.
- SINGH P, XU ZD, DAI BS, RAJARAMAN S, RUBIN N, DHRUVA B: Incomplete processing of progastrin ex- pressed by human colon cancer cells: Role of noncarb-oxyamidated gastrins. Am .J. Physiol. (1994) 226:459–468.
- NEGRE J, FAGOT REVURAT P, VAYSSE N, REHFELD JF, PRADAYROL L: Progastrin induced autocrine/intracrine proliferative effects on pancreatic rat tumoural cells (A114-4). Gastroenterology (1994) 106:A309.
- SEVA C, DICKINSON CJ, YAMADA T: Growth-promoting effects of glycine-extended progastrin. Science (1994)265:410–412.
- First demonstration of the proliferative capacity of glycine-extended 8astrin–17.
- WANK SA, PISEGNA JR, DE WEERTH A: Brain and gastro-intestinal cholecystokinin receptor family: structure and functional expression. Proc. Natl. Acad. Sci. USA (1992) 89:8691–8695.
- KOPIN AS, LEE Y-M, MCBRIDE EW, MILLER U. LU M, LI HY, ET AL.: Expression cloning and characterisation ofthe canine parietal cell gastrin receptor. Proc. Natl. Acad. Sci. USA (1992) 89:3605–3609.
- Identification that the peripheral and central gastrin/CCK-B receptors were the same.
- NAKATA H, MATSUI T, ITO M, TANIGUCHI T, NARIBAYASHI Y, NAKAMURA A, ET AL.: Cloning and characterisation of gastrin receptor from ECL carcinoid tumour of Mastortrys natalensts. Biochem. Biophys. Res. Comm. (1993) 187:1151–1157.
- PISEGNA JR, DE WEERTH A, HUPPI K, WANK S: Molecular cloning of the human brain and gastric cholecystokininreceptor: structure, functional expression and chromo-somal localisation. Biochem. Biophys. Res. Comm. (1992) 189:296–302.
- Cloning of the human gastrin/CCK-B receptor.
- LEE Y-M, BEINBORN M, MCBRIDE W, LU M, KOLAKOWSKI LF, KOPIN AS: The distinction between 'gastrin' and `CCK-B' receptor subtypes may no longer be justified. Gastroenterology (1993) 104:A836.
- MIYAKE A, MOCHIZUKA S, KAWASHIMA H: Charac-terisation of cloned human cholecystokinin-B receptor as a gastrin receptor. Biochem. Pharmacol. (1994) 47:1339–1343.
- SONG I, BROWN DR, WILTSHIRE RN, GANTZ I, TRENT JM,YAMADA T: The human gastrin/cholecystokinin type B receptor gene: alternative splice donor site in exon 4 generates two variant mRNAs. Proc. Natl. Acad. Sci. USA (1993) 90:9085–9089.
- ITO M, IWATA N, TANIGUCHI T, MURAYAMA T, CHIHARA K, MATSUI T: Functional characterisation of two cholecystokinin-B/g-astrin receptor isoforms: A prefer-ential splice donor site in the human receptor gene. Cell Growth Dig. (1994) 5:1127–1135.
- SCEMAMA JL, FOURMY D, ZAHIDI A, PRADAYROL L, SUSINI C, RIBET A: Characterisation of gastrin receptors on a rat pancreatic acinar cell line (AR4-4). A possible model for studying gastrin mediated cell growth and proliferation. Gut (1987) 28:233–236.
- ZHOU W, POVOSKI SP, LONGNECKER DS, BELL RH, Jr.: Novel expression of gastrin (cholecystokinin-B) recep-tors in azaserine-induced rat pancreatic carcinoma: receptor determination and characterisation. Cancer Res. (1992) 52:6905–6911.
- DE WEERTH A, NON SCHRENCK T, MIRAU S, RAEDLER H,GRETEN H, ICALTHOFF H: Human pancreatic cancer celllines express the CCK-B/gastrin receptor. AGA Abstract (1994):A289.
- WATSON SA, CROSBEE DM, MORRIS DL, ROBERTSON JF,MAKOVEC F, ROVATI LC, HARDCASTLE JD: Therapeutic effect of the gastrin receptor antagonist CR-2093 on gastrointestinal tumour cell growth. Br. J. Cancer (1992) 65:879–883.
- FRua-rr H, GAZDAR AF, PARK J-A, OIE H, JENSEN RT:Characterization of functional receptors for gastroin-testinal hormones on human colon cancer cells. Cancer Res. (1992) 52:1114–1122.
- ISHIZUKA J, MARTINEZ J, TOWNSEND CM, Jr., THOMPSON JC: The effect of gastrin on growth of human stomach cancer cells. Ann. Surg.(1992) 215:528–535.
- UPP JR, SINGH S, TOWNSEND CM, THOMPSON JC: Clinical significance of gastrin receptors in human colon can-cers. Cancer Res. (1989) 49:488–492.
- WEINSTOCK J, BALDWIN GS: Binding of gastrin-17 to human gastric carcinoma cell lines. Cancer Res. (1988) 48:932–937.
- First publication on a putative low affinity gastrin receptor.
- BALDWIN GS, CHANDLER R, SCANLON DB, WEINSTOCK J: Identification of a gastrin binding protein in porcine gastric mucosal membranes by covalent cross-linking with iodinated gastrin 17.J. Biol. Chem. (1986) 261:12252–12257.
- BALDWIN GS, CHANDLER R, GREGO B, RUBTRO MR, SERF KU, WEINSTOCK J: Int. J. Biochem. (1993) 26:529–538.
- BALDWIN GS: Comparison of sequences of the 78 ItDa gastrin-binding protein and some enzymes involved in fatty acid oxidation. Comp. Biochem. Physiot (1993) 104B:55–61.
- BALDWIN GS: Binding of progastrin fragments to the 78 IcDa gastrin-binding protein. FESS Let t. (1995) 359:97–100.
- IMDAHL A, EGGSTEIN S, BALDWIN GS, FARTHMANN EH: Expression of gastrin, gastrin/CCK-B and gastrin/CCK-C receptors in human colorectal carcinomas. Gastroen-terology (1995) 108:A500.
- SEVA C, DICKINSON CJ, SAWADA M, YAMADA T: Charac-terisation of the glycine-extended gastrin (G-gly) recep-tor on AR4-2J cells. Gastroenterology (1995) 108:A742.
- SINGH P, OWLIA A, ESPEIJO R, DAI B: Novel gastrin receptors mediate mitogenic effects of gastrin and proc-essing intermediates of gastrin on Swiss 3T3 fibroblasts. Absence of detectable cholecystokinin (CCK)-A and CCK-B receptors. J. Biol. Chem. (1995) 270:8429–8438.
- MIYAKE A: A truncated isoform of human CCK-B/gastrin receptor generated by alternative usage of a novel exon. Biochem. Biophys. Res. Commun. (1995) 208:230–237.
- ROVATI AL: The relationship between chemical struc- ture of a new dicarboxylic amino acid derivative and anti-gastrin activity in the rat. Br. J. Pharmacol. (1968) 34:677–682.
- One of the first non-selective gastrin receptor antagonists.
- WATSON SA, MORRIS DL, DURRANT LG, ROBERTSON JF, HARDCASTLE JD: Inhibition of gastrin-stimulated growth of gastrointestinal tumour cells by octreotide and the gastrin/cholecystokinin receptor antagonists, proglumide and lorglumide. Eur. J Cancer (1992) 28A:1462–1467.
- BEAUCHAMP RD, TOWNSEND 04, Jr., SINGH P, GLASS EJ, THOMPSON JC: Proglumicle, a gastrin receptor antago-nist, inhibits growth of colon cancer and enhances survival in mice. Ann. Surg. (1985) 202:303–308.
- SEVA C, SCEMAMA JL, BASTIE MJ, PRADAYROL L, VAYSSE N: Lorglumkle and loxiglumide inhibit gastrin-stimu-lated DNA synthesis in a rat tumoural adnar pancreatic cell line. Cancer Res. (1990) 50:5829–5833.
- PIONTEK MK, HENGELS KJ: Differential mode of action of high-and low-affinity CCK/gastrin receptor antago-nists in growth inhibition of gastrin-responsive human gastric adenocarcinoma cells in vitro. Anticancer Res. (1993) 13:715–720.
- Demonstration of the gastrin selectivity of gastrin receptor antago-nists.
- BALDWIN GS: Antiproliferative gastrin cholecystokininreceptor antagonists target the 78 kDa gastrin-binding protein. Proc. Natl. Acad. Sci. USA (1994) 91:7593–7597.
- HARRISON JD, JONES JA, MORRIS DL: The effect of gastrinreceptor antagonist proglumide on survival in gastric carcinoma. Cancer (199o) 66:1449-1452.
- MORRIS DL, CHARNLEY RM, BALLANTYNE KC, JONES J: A pilot randomized control trial of prog,lumide (a gastrin receptor antagonist) in advanced colorectal cancer. Eur. J. Surg. Oncol. (1990) 16:423–425.
- CHANG RSL, LOTH VS, MONAGHAN RL, ET AL.: A potent non-peptide cholecystokinin antagonist selective for peripheral tissue isolated from Aspergilius alliacous. Science (1985) 230:177–179.
- CHANG RSL, LOTFI VJ: Biochemical and pharmacologi-cal characterisation of an extremely potent and selec-tive nonpeptide cholecystokinin antagonist. Proc. Natl. Acad. Sci. USA (1986) 83:4923–4926.
- BOCK MG, DIPARDO RM, EVANCS BE, ET AL.: Ben-zodiazepine gastrin and brain cholecystokinin receptor ligands; L-365,260. J. Med. Chem. (1989) 32:13–16.
- LOUT VJ, CHANG RSL: A new potent and selective esnon-peptide gastrin antagonist and brain cholecystok-hiln receptor (CCK-B) ligand: L-365,260. Eur. J. Pharma-col. (1989) 162:273–280.
- Identification of the first gastrin/CCK-B receptor selective antagonist.
- HUGHES j, BODEN P, COSTALL B, DOMENEY A, KELLY E, HORWELL DC, HUNTER JC, PINNOCK RD, WOODRUFF GN: Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity. Proc. Natl. Acad. Sci. USA (1990) 87:6728–6732.
- ROMANI R, HOWES LG, MORRIS DL: New gastrin receptor antagonists (GRAs), possible treatment for colon can-cer. Gut (1994) 35(Suppl.):S32.
- WATSON SA, MORRIS TM, ROBINSON G, VARRO A, MICHAELI D: Therapeutic effects of anti-gastrin antibodies raised by Gastrimmune on a human gastric cancer ascites line, MGLVA1 . Proc. AACR (1995) 36:253. Therapeutic application of Gastrimrnune in human gastric cancer fuelled by the autocrine pathway.
- KUDOH T, KUWAHARA T, FUJIU M, YANAGISAWA M, NAGASE H, TAKAMIYA M, NAKANO A, YOSHIZAKI H, ARISAWA M, YOKOSE K: Ro-09-1540, a novel dass of CCK-B receptor antagonist; Effects on [1251]-CCK8 bind-ing and intracellular level of calcium in GH3 cells. jpn. J. Pharmacol. (1994) 64(Suppl.):13439.
- PATEL S, SMITH AJ, CHAPMAN KL, ET AL.: Biologicalproperties of the benzodiazepine amidine derivative L-740,093, a chokcystokinin-B/gastrin receptor antago-nist with high affinity in vitro high potency in vivo. Mol. Pharmacol. (1994) 46:943–948.
- SAFFOURI B, WEIR GC, BITAR K, MAKHLOUF G: Gastrinand somatostatin secretion by perfused rat stomach: functional linkage of antral peptides. Am. J. Physiol. (1980) 238:G495–G501.
- DELVALLE J, YAMADA T: Amino adds and amines stimu-late gastrin release from canine antral 6-cells via dif-ferent pathways. J. Clin Invest. (1990) 85:139–143.
- BRAND Sj, STONE D: Reciprocal regulation of antral gastrin and somatostatin gene expression by omepra-zole-induced achlorhydria. J. Clin. Invest. (1988) 82:1059–1066.
- BAUER W, BRINER U, DOEFNER W, ET AL.: SMS 201–995:a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci (1982) 31:1133–1140.
- SCHALLY AV: Oncologkal applications of somatostatinanalogues. Cancer Res. (1988) 48:6977–6985.
- RADULOVIC SS, MILOVANOVIC SR, CAI R-Z, SCHALLY AV:The binding of bombesin and somatostatin and their analogs to human colon cancer. PSEBM (1992) 200:394–401.
- REUBI JC, LAISSUE J, WASER B, HORISBERGER U, SCHAERJC: Expression of somatostatin receptors in normal, Inflamed and neoplastic human gastrointestinal tis-sues. Ann. NY Acad. Sci. (1994) 733:122–137.
- LAWS SAM, GOUGH AC, BAINS MA, PRIMROSE JN: The distribution of somatostatin receptor subtypes in nor-mal and malignant colonic epithelium. Gut (1995) 37\(Suppl. 2)A36.
- Thorough initial study showing complexity of somatostatin receptor subtype expression on colonic tumours.
- MILLER GV, FARMERY SM, WOODHOUSE LF, PRIMROSE JN: Somatostatin binding in normal and malignant human gastrointestinal mucosa. Br. J. Cancer (1992) 66:391–395.
- GILLESPIE J, POSTON GJ, SCHACHTER M, GUILLOU PJ:Human pancreatic cancer cell lines do not express receptors for somatostatin. Br. J. Cancer (1992) 66:438–487.
- LEBOVITZ P, FINLEY GG, MELHEM M, DAGNAL E, MEISLER AT: The role of gastrin in colorectal cancer cell lines. Proc. AACR (1994) 35:42.
- Identification at the transcriptional level of gastrin/somatostatin interactions.
- DY DY, WHITEHEAD RH, MORRIS DL: SMS 201-995 inhib-its in vitro and in vivo growth of human colon cancer. Cancer Res. (1992) 52:917–923.
- DAVIES N, KYNASTON H, YATES J, NOTE DM, NASH J, TAYLOR BA, JENKINS SA: Octreotide inhibits the growth and development of 3 types of experimental liver me-tastases. Br. J. Surg. (1995) 82:840–843.
- LIEBOW C, REILLY C, SERRANO M, SCHALLY AV: Somato- statin analogues inhibit growth of pancreatic cancer bystimulating tyrosine phosphatase. Proc. Natl. Acad. Sci. USA (1989) 86:2003–2007.
- Potential intracellular mechanism for the somatostatin-mediated inhibition of the mitogenic activity of gastrin.
- CASCINU S, DEL-FERRO E, CATALANO G: A randomisedtrial of octreotide vs. best supportive care only in advanced gastrointestinal cancer patients refractory to chemotherapy. Br. J. Cancer (1995) 71:97–101.
- SMITH JP, DOLL D, CROITORU R, THORNTON C, PERRY MC: Octreotide has no effect on advanced colon cancer. J. aim Gastroenterol. (1994) 18:245–247.
- EBERT M, FRlESS H, SEGER HG, BUCHLER MW: Role of octreotide in the treatment of pancreatic cancer. Diges-tion (1994) 35:48–51.
- FRIESS H, BUCHLER M, EBERT M, MALFERTHEINER P, DENNLER JH, BEGER HG: Treatment of advanced pancre-atic cancer with high dose octreotide. Int. J. Pancreatol-ogy (1993) 14:290–291.
- ROSENBERG L, BARKUN AN, DENIS MH, POLLAK M: Low dose octreotide and tamoxifen in the treatment of adenocarcinoma of the pancreas. Cancer(1995) 75:23–28.
- RADULOVIC S, COMARUSCHALLY AM, MILOVANOVIC S, SCHALLY AV: Somatostatin analogue RC-160 and LHRH antagonist SB-75 inhibit growth of MIA PACA-2 human pancreatic cancer xenografts in nude mice. Pancreas (1993) 8:88–97.
- QIN Y, ERTL T, GROOT K, HORVATH J, CAI RZ, SCHALLY AV: Somatostatin analog RC-160 inhibits growth of CFPAG1 human pancreatic cancer cells in vitro and intracellular production of cyclic adenosine mono-phosphate. Int. J. Cancer (1995) 60:694–700.
- PINSKI J, HALMOS G, YANO T, SZEPESHAZI K, QIN YE, ERTL T, SCHALLY AV: Inhibition of growth of MIEN45 human gastric-carcinoma xenografts in nude mice by treatment with bombesin gastrin-releasing peptide an-tagonist (RC-3095) and somatostatin analog RC-160. Int. J. Cancer (1994) 57:574–580.
- RADULOVIC S, SCHALLY AV, REILE H, HALMOS G, SZEPESHAZI K, GROOT K, MILOVANOVIC S, MILLER G, YANO T: Inhibitory effects of antagonists of bombesin, gastrin-releasing peptide (GRP) and somatostatin ana-log (RC-160) on growth of HT-29 human colon cancers In nude mice. Acta Oncologica (1994) 33:693–701.
- QIN Y, SCHALLY AV, WILLEMS G: Treatment of liver metastases of human colon cancers in nude mice with somatostatin analogue RC-160. Int. J. Cancer (1992) 52:791–796.
- WATSON SA, MORRIS TM, CROSBEE DM, STEELE RJC, HARDCASTLE JD: The somatostatin analogue, RC-160 Inhibits hepatic invasion by a human colonic xenograft. Br. Ass. Surg. Oncol. (1994). Abstract.
- POSTON GJ: Somatostatin and the treatment of pancre-atic can. Annals of the Royal College of Surgeons of England (1994) 76:172–174.
- ICEYES SR, TAYLOR JE, BOGDEN AE, COY DH: Antiprolif-erative activity and receptor binding affinity of soma-tostatin (SS) analogs using AR4-2J rat pancreas tumour cells in vivo and in vitro. Proc. AACR (1993). Abstract 2040.
- BOLD RJ, WARREN RE, ISHIZUKA J, CHOCHUNG YS, TOWNSEND CM, THOMPSON JC: Experimental gene therapy of human colon cancer. Sutgery (1994) 116:189–196.
- SCHMIDT BF, HERNANDEZ L, ROUZER C, ETAL.: Peptide-linked 1,3-dialky1-3-acyltriazenes: gastrin receptor di-rected antineoplastic. J. Med. Chem. (1994) 116:3812–3818.
- BLALOCK JE, SMITH EM: Hydropathic anti-complemen-tarity of amino arkis based on the genetic code. Biochem. Biophys. Res. Comm. (1984) 121:203–207.
- KYTE J, DOOLITTLE RF: A simple method for displaying the hydropathk character of a protein. J. Mol. Biol. (1982) 157:105–132.
- MCGLTIGAN JE, CAMPBELL-THOMPSON M: Complemen-tary peptide to the carboxyl-terminal tetrapeptide of gastrin. Gastroenterology (1992) 103:749–758.
- GARNER A, HAMPSON SE, STAMER AM, CURRY BJ, VAL-CACCIA BE, WOODBURN JR, ET AL.: Effect of inhibition of endogenous gastrin on growth of gastrointestinal tumours. Gut (1992) 33:S63.
- MAKISHIMA R, LARKIN D, MICHAELI D, GAGINELLA TS: Active immunization against gastrin-17 with an N-ter-minal derived immunogen inhibits gastric and duode-nal lesions in rats. Gastroenterology (1995) 106:Abstract A824.
- Description of potential benign applications of the G17-specific immunogen, Gastrimmune.
- WATSON SA, MICHAEL' D, MORRIS TM, ROBINSON G, OHARDCASTLE JD: Gastrimmune inhibits the primary andsecondary growth of 2 rat colon carcinomas. Proc. AACR (1994) 35:257.
- Initial report detailing therapeutic effects of active immunisation with Gastrimmune in colon cancer.
- JUSTIN TA, WATSON SA, MICHAELI D, HARDCASTLE JD, STEELE RJC: Gastric add suppression using anti-gastrin-17 antibodies produced by a gastrin immunogen, Gas-trimmune, in an in vivo pig modeL Gastroenterology (1995) 108:A508.
- WATSON SA, MICHAEL' D, GRIMES S, MORRIS TM, CROS-BEE D, WILKINSON M, ROBINSON G, ROBERTSON JER, STEELE RJC, HARDCASTLE JD: Anti-gastrin antibodies raised by Gastritrunune inhibit growth of the human colorectal tumour AP5. Int. J. Cancer (1995) 61:233–240.
- WATSON SA, MICHAELI D, MORRIS TM, VARRO A, ROBIN- SON G, JUSTIN TA, HARDCASTLE JD: Gastrimmune re-duces lung metastases in a human colorectal modeL Gut (1995) 37\(Suppl. 2)A37.
- Enhanced therapeutic effect of Gastrimmune in secondary spread.